

**CURRENT REPORT 28/2022**  
**December 2, 2022**

**Decision to conduct public offering of J series shares in December 2022**

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Issuer") informs that the Management Board of the Issuer adopted on December 1, 2022 a resolution on its intent to conduct a public offering of no more than 4,764,674 new Series J ordinary bearer shares with a nominal value of PLN 0.40 ("Series J Shares") in December 2022.

Series J Shares are issued on the basis of the resolution of the Management Board of the Company of 5 October 2022, the adoption of which was announced in a current report No 22/2022 of 5 October 2022.

The Management Board of the Company aims to publish the prospectus drawn up in connection with the public offering of the J Series Shares and the intention to apply for admission and introduction of the Series J Shares to trading on the regulated market (main market) of the Warsaw Stock Exchange S.A. (the "Prospectus"), promptly after the approval of the Prospectus by the Financial Supervision Authority (Komisja Nadzoru Finansowego).

Terms of the public offering of the Series J Shares will be provided in the Prospectus.

**Legal basis:** Article 17.1 of MAR

**Representatives of the Issuer:**

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board